Jeonbuk National University Hospital | Clinical Pharmacology Center
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
To evaluate the safety and anti-tumor activity of GEN1042 in patients with metastatic or locally advanced solid tumors.
Full description
This is an open-label, multicenter phase 1/2 study designed to assess the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of GEN1042 administered as a monotherapy or in combination in subjects with metastatic or locally advanced solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Monotherapy - Dose Escalation and Dose Expansion Parts
Combination Therapy - Dose Expansion Part
General (all phases):
Key Exclusion Criteria:
Monotherapy - Dose Escalation and Dose Expansion Parts
Combination Therapy - Dose Expansion Part
General (all phases)
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
1,287 participants in 2 patient groups
Loading...
Central trial contact
Genmab A/S Trial Information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal